Comparative Pharmacology
Head-to-head clinical analysis: CHILDREN S ADVIL versus EC NAPROSYN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHILDREN S ADVIL versus EC NAPROSYN.
CHILDREN'S ADVIL vs EC-NAPROSYN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis. This leads to decreased pain, inflammation, and fever through peripheral and central mechanisms.
Naproxen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) enzymes, thereby reducing prostaglandin synthesis, which mediates inflammation, pain, and fever.
Ibuprofen 200-400 mg orally every 4-6 hours as needed; maximum 1200 mg/day without prescription.
500-1000 mg orally twice daily; maximum 1500 mg/day.
None Documented
None Documented
Terminal elimination half-life is 1.9–2.3 hours in children. In neonates, half-life is prolonged (up to 6 hours). Clinical context: Requires dosing every 6–8 hours for sustained antipyresis.
Terminal elimination half-life 12-17 hours (mean 14 hours); prolonged in elderly and renal impairment
Renal excretion of conjugated metabolites (glucuronide and sulfate) accounts for ~90% of the administered dose. Less than 5% is excreted unchanged in urine. Biliary/fecal elimination is minor (<5%).
Renal (95%) as unchanged drug (10%) and conjugated metabolites (60%) and other metabolites (25%); biliary/fecal (5%)
Category C
Category C
NSAID
NSAID